On October 14, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police raided an industrial unit in Birmingham, seizing over 12,000 counterfeit retatrutide and tirzepatide pens with an estimated value of approximately £2 million. The operation also recovered packaging materials for around 30,000 additional products.
The MHRA stated that the seized products had not been assessed for safety, quality, or effectiveness and could contain harmful contaminants. Retatrutide has not been authorised for use in the United Kingdom outside of legitimate clinical trials.
The raid represents one of the largest single-seizure operations targeting counterfeit GLP-1 weight-loss drugs in the UK, signalling intensifying enforcement against the illegal trade in unapproved peptides.
What happened
On October 14, MHRA enforcement officers, working with West Midlands Police, conducted a raid on a Birmingham industrial unit. Authorities seized more than 12,000 counterfeit pens purporting to contain retatrutide or tirzepatide, weight-loss treatments in the GLP-1 drug class. The seized products carried an estimated combined value of approximately £2 million.
In addition to the completed pens, the operation recovered packaging materials sufficient for roughly 30,000 further products.
The MHRA stated that retatrutide has not been authorised for use in the UK outside of legitimate clinical trials. The agency said the seized products had not undergone any assessment for safety, quality, or effectiveness and could contain harmful contaminants, posing potential health risks to anyone using them.
The MHRA urged individuals seeking GLP-1 medicines to obtain them only from registered pharmacies with a valid prescription.
Why it matters
The Birmingham raid is one of the largest single-seizure operations targeting counterfeit GLP-1 drugs recorded in the UK. It follows at least three prior enforcement actions in October 2025, February 2026, and May 2026, pointing to an escalating UK campaign against the illicit distribution of unapproved weight-loss peptides.
For consumers, the MHRA’s warning underscores the potential dangers of obtaining GLP-1 medicines outside regulated channels. Counterfeit products that have not been assessed for safety or quality could contain harmful contaminants.
The enforcement action also has implications for UK compounding pharmacies, online peptide vendors selling to UK customers, and telehealth companies serving UK patients. As MHRA enforcement intensifies, these groups face increasing scrutiny over how GLP-1 products are sourced, distributed, and prescribed.
What to watch next
- Additional MHRA and police enforcement actions targeting counterfeit GLP-1 supply networks
- Laboratory analysis of the seized products to determine their actual contents and any contamination
- Any arrests, charges, or prosecutions connected to the Birmingham operation
- Further regulatory clarification on the authorisation status of retatrutide in the UK
Sources
GOV.UK — Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police
Industry information only. Not medical or legal advice.
